CC BY-NC-ND 4.0 · Avicenna J Med 2012; 02(03): 77-78
DOI: 10.4103/2231-0770.102284
LETTER TO THE EDITOR

Hepatitis A vaccination in developing countries: Is Syria next?

Ghaith Habboub
Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio, USA
,
Shadi M Alhalabi
Yale School of Public Health, Yale University, New Haven, CT, USA
,
Ghaith Mousabasha
Damascus University Faculty of Medicine, Damascus, Syria
,
Zaid AL-Faham
Damascus University Faculty of Medicine, Damascus, Syria
› Author Affiliations


Publication History

Article published online:
09 August 2021

© 2012. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 
  • References

  • 1 Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol 2005;34:600-9.
  • 2 Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-care centers. A community-wide assessment. N Engl J Med 1980;302:1222-7.
  • 3 Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infection in adults. Am J Epidemiol 1985;122:226-33.
  • 4 Glikson M, Galun E, Oren R, Tur-Kaspa R, Shouval D. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore) 1992;71:14-23.
  • 5 Novotny TE. US Department of Health and Human Services: A need for global health leadership in preparedness and health diplomacy. Am J Public Health 2006;96:11-3.
  • 6 Tandon BN. Ninth Triennial International Symposium on Viral Hepatitis and Liver Diseases. Rome 21 st -25 th April 1996. Trop Gastroenterol 1996;17:77-83.
  • 7 Bell BP. Hepatitis A and hepatitis B vaccination of patients with chronic liver disease. Acta Gastroenterol Belg 2000;63:359-63.
  • 8 Centers for Disease Control and Prevention. Hepatitis A Information for Health Professionals. Available from: http://www.cdc.gov/hepatitis/HAV/index.htm. [Last accessed on 2012 Jun 05].
  • 9 Domínguez A, Oviedo M, Carmona G, Batalla J, Bruguera M, Salleras L, et al. Impact and effectiveness of amass hepatitis A vaccination programme of preadolescents seven years after introduction. Vaccine 2008;26:1737-41.
  • 10 Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005;294:194-201.
  • 11 Westblom TU, Gudipati S, DeRousse C, Midkiff BR, Belshe RB. Safety and immunogenicity of an inactivated hepatitis A vaccine: Effect of dose and vaccination schedule. J Infect Dis 1994;169:996-1001.
  • 12 Antaki N, Kebbewar MK. Hepatitis A seroprevalence rate in Syria. Trop Doct 2000;30:99-101.
  • 13 Barzaqua BN. Hepatitis A shifting epidemiology in South-East and China. Vaccine 2000;18 (Suppl):S61-4.
  • 14 Sacy RG, Haddad M, Baasiri G, Khoriati A, Gerbaka BJ, Abu-Elyazeed R. Hepatitis A in Lebanon: A changing epidemiological patent. Am J Trop Med Hyg 2005;73:453-6.
  • 15 Battikhi MN, Battikhi EG. The seroepidemiology of Hepatitis A virus in Amman, Jordan. New Microbial 2004;27:215-20.
  • 16 Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, et al. A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-7.
  • 17 Niu MT, Salive M, Krueger C, Ellenberg SS. Two-year review of hepatitis A vaccine safety: Data from the Vaccine Adverse Event Reporting System (VAERS). Clinical Infectious Diseases 1998;26:1475-6.
  • 18 Mawhorter SD. Who should receive hepatitis A vaccine? Cleve Clin J Med 2001;68:825-7.
  • 19 Rein DB, Hicks KA, Wirth KE, Billah K, Finelli L, Fiore AE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 2007;119:e12-21.
  • 20 Domínguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination programme in preadolescents. Vaccine 2003;21:698-701.
  • 21 Lopaclo PL, Salleras L, Barbuti S, Germinario C, Bruguera M, Buti M, et al. Hepatitis A and B in children and adolescents--what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 2000;19:470-4.